No Data
No Data
Express News | Kintara Therapeutics Inc - Received a Letter From Nasdaq Advising That Company Had Been Granted a 180-Day Extension to December 9
Express News | Kintara Therapeutics:On June 4,Co Submitted Request to Nasdaq for Additional 180-Day Extension to Regain Compliance With Minimum Bid Price Requirement
12 Health Care Stocks Moving In Tuesday's Intraday Session
GainersConcord Medical Services (NYSE:CCM) shares moved upwards by 51.9% to $1.2 during Tuesday's regular session. The market value of their outstanding shares is at $52.1 million. Annexon (NASDAQ:ANN
Express News | Kintara Therapeutics Inc: Phase 3 Trial Is Expected to Begin Enrollment in 2H 2024
Express News | Kintara Therapeutics Inc: Tuhura's Lead Candidate, Ifx-2.0, Was Safe and Well Tolerated at Once Weekly Dosing for 3 Weeks
Express News | Tuhura Biosciences and Kintara Therapeutics Announce Positive Results From Phase 1B Trial of Ifx-2.0, a Novel Personalized Cancer Vaccine, in Checkpoint Inhibitor Resistant Advanced Merkel Cell Carcinoma (Mcc) and Cutaneous Squamous Cell Carcinoma (Cscc)
No Data